Meta-Analysis Comparing Potent Oral P2Y(12) Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

BACKGROUND: In patients with atrial fibrillation (AF) receiving percutaneous coronary intervention (PCI), current guidelines recommend against combining potent oral P2Y(12) inhibitors (i.e. ticagrelor or prasugrel) with oral anticoagulant (OAC) therapy, but the evidence is limited. OBJECTIVE: The ai...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Cardiovasc Drugs
Hlavní autoři: Casula, Matteo, Fortuni, Federico, Ferlini, Marco, Fabris, Francesca, Oltrona Visconti, Luigi, Leonardi, Sergio
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2020
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7956939/
https://ncbi.nlm.nih.gov/pubmed/32895853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40256-020-00436-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky